share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bhatia Sangeeta N.

SEC announcement ·  May 4 04:10
Summary by Futu AI
Sangeeta N. Bhatia, associated with Vertex Pharmaceuticals Inc. (VRTX), completed a sale of company stock on May 2, 2024. The transaction involved the disposal of 467 shares of common stock at a price of $402.95 per share, resulting in a total market value of $188,177.65. This sale followed an acquisition of 1,001 shares on May 1, 2024, which were granted at no cost. After these transactions, Bhatia's direct holdings in Vertex Pharmaceuticals totaled 4,435 shares. The sale took place in the open market and is part of the normal course of stock trading for company insiders.
Sangeeta N. Bhatia, associated with Vertex Pharmaceuticals Inc. (VRTX), completed a sale of company stock on May 2, 2024. The transaction involved the disposal of 467 shares of common stock at a price of $402.95 per share, resulting in a total market value of $188,177.65. This sale followed an acquisition of 1,001 shares on May 1, 2024, which were granted at no cost. After these transactions, Bhatia's direct holdings in Vertex Pharmaceuticals totaled 4,435 shares. The sale took place in the open market and is part of the normal course of stock trading for company insiders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.